Bryn Mawr Capital Management LLC Acquires 6,170 Shares of Zoetis Inc. (NYSE:ZTS)

Bryn Mawr Capital Management LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 70.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,888 shares of the company’s stock after acquiring an additional 6,170 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Zoetis were worth $2,938,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Jackson Hole Capital Partners LLC bought a new position in Zoetis during the fourth quarter valued at approximately $4,148,000. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Zoetis by 12.7% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 565,699 shares of the company’s stock valued at $111,652,000 after purchasing an additional 63,950 shares during the period. Sandhill Capital Partners LLC boosted its stake in shares of Zoetis by 2.1% during the fourth quarter. Sandhill Capital Partners LLC now owns 132,606 shares of the company’s stock valued at $26,173,000 after purchasing an additional 2,666 shares during the period. Abbrea Capital LLC boosted its stake in shares of Zoetis by 5.1% during the fourth quarter. Abbrea Capital LLC now owns 2,065 shares of the company’s stock valued at $408,000 after purchasing an additional 100 shares during the period. Finally, Syon Capital LLC boosted its stake in shares of Zoetis by 19.1% during the fourth quarter. Syon Capital LLC now owns 5,156 shares of the company’s stock valued at $1,018,000 after purchasing an additional 828 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Roxanne Lagano sold 363 shares of Zoetis stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares in the company, valued at approximately $4,037,257.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 2,209 shares of company stock worth $371,293 over the last three months. 0.12% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ZTS has been the subject of a number of analyst reports. Barclays dropped their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Stifel Nicolaus dropped their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Piper Sandler reaffirmed an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, The Goldman Sachs Group raised their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average price target of $218.00.

Zoetis Stock Up 3.3 %

Zoetis stock traded up $5.06 on Friday, hitting $158.42. 5,236,447 shares of the stock traded hands, compared to its average volume of 3,117,213. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The business’s fifty day simple moving average is $171.79 and its 200 day simple moving average is $179.29. The firm has a market cap of $72.45 billion, a P/E ratio of 31.25, a price-to-earnings-growth ratio of 2.31 and a beta of 0.85.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter in the previous year, the business earned $1.15 earnings per share. Zoetis’s revenue was up 8.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Zoetis Inc. will post 5.79 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. Zoetis’s payout ratio is presently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.